Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401941 | 1.00 | ESR1 (0.55) | ESR1ESR2FFAR1 | |
| SCHEMBL223922 | 1.00 | ESR1 (0.55) | ESR1ESR2FFAR1 | |
| SCHEMBL17385861 | 0.88 | FFAR1 (0.54) | FFAR1 | |
| SCHEMBL14563252 | 0.88 | FFAR1 (0.64) | FFAR1 | |
| SCHEMBL15248919 | 0.88 | FFAR1 (0.64) | FFAR1 | |
| SCHEMBL17385863 | 0.88 | FFAR1 (0.54) | FFAR1 | |
| SCHEMBL16810728 | 0.86 | ESR1 (0.54) | ESR1ESR2FFAR1 | |
| SCHEMBL14496288 | 0.86 | FFAR1 (0.52) | FFAR1 | |
| SCHEMBL24724162 | 0.86 | FFAR1 (0.59) | FFAR1 | |
| SCHEMBL13140296 | 0.86 | FFAR1 (0.59) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | CELON PHARMA S.A. (PL) | 2024-04-23 | — | — | US | disclosed |
| EP-3737470-B9 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2024-03-13 | — | — | EP | disclosed |
| CN-111757770-B | 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11731961-B2 | Phenyl propionic acid derivatives and uses thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-22 | — | — | US | disclosed |
| US-11731961-B2 | Phenyl propionic acid derivatives and uses thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-22 | — | — | US | disclosed |
| US-11731961-B2 | Phenyl propionic acid derivatives and uses thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-22 | — | — | US | disclosed |
| EP-3555076-B1 | NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | IL DONG PHARMA (KR) | 2023-04-05 | — | — | EP | disclosed |
| US-20230022803-A1 | NOVEL CRYSTALLINE FORM OF GPR40 AGONIST | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| EP-3737470-B1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2022-12-14 | — | — | EP | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC (US) | 2006-11-30 | — | — | US | disclosed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | ESR1 2720/4885ESR2 1821/4885FFAR1 1245/4885 |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | ESR1 3291/4885ESR2 2450/4885FFAR1 51/4885 |
| US-20230022803-A1 | NOVEL CRYSTALLINE FORM OF GPR40 AGONIST | GPR65, GPR55, GPR4 | ESR1 386/4885ESR2 668/4885FFAR1 14/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | ESR1 2720/4885ESR2 1821/4885FFAR1 1245/4885 |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | IAPP, INSR, GPR119 | ESR1 1798/4885ESR2 1018/4885FFAR1 931/4885 |
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | GPR119, FFAR1, GPR65 | ESR1 384/4885ESR2 425/4885FFAR1 2/4885 |
| US-11731961-B2 | Phenyl propionic acid derivatives and uses thereof | GPR119, GPR65, GPR55 | ESR1 1326/4885ESR2 651/4885FFAR1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.